Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes

Show full item record




FinnDiane Study Grp , Pongrac Barlovic , D , Harjutsalo , V , Sandholm , N , Forsblom , C & Groop , P-H 2020 , ' Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes ' , Diabetologia , vol. 63 , no. 9 , pp. 1847-1856 . https://doi.org/10.1007/s00125-020-05201-9

Title: Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes
Author: FinnDiane Study Grp; Pongrac Barlovic, Drazenka; Harjutsalo, Valma; Sandholm, Niina; Forsblom, Carol; Groop, Per-Henrik
Contributor organization: Research Programs Unit
University of Helsinki
Nefrologian yksikkö
HUS Abdominal Center
Helsinki University Hospital Area
CAMM - Research Program for Clinical and Molecular Metabolism
Faculty of Medicine
Department of Medicine
Per Henrik Groop / Principal Investigator
Date: 2020-09
Language: eng
Number of pages: 10
Belongs to series: Diabetologia
ISSN: 0012-186X
DOI: https://doi.org/10.1007/s00125-020-05201-9
URI: http://hdl.handle.net/10138/324375
Abstract: Aims/hypothesis Lipid abnormalities are associated with diabetic kidney disease and CHD, although their exact role has not yet been fully explained. Sphingomyelin, the predominant sphingolipid in humans, is crucial for intact glomerular and endothelial function. Therefore, the objective of our study was to investigate whether sphingomyelin impacts kidney disease and CHD progression in individuals with type 1 diabetes. Methods Individuals (n = 1087) from the Finnish Diabetic Nephropathy (FinnDiane) prospective cohort study with serum sphingomyelin measured using a proton NMR metabolomics platform were included. Kidney disease progression was defined as change in eGFR or albuminuria stratum. Data on incident end-stage renal disease (ESRD) and CHD were retrieved from national registries. HRs from Cox regression models and regression coefficients from the logistic or linear regression analyses were reported per 1 SD increase in sphingomyelin level. In addition, receiver operating curves were used to assess whether sphingomyelin improves eGFR decline prediction compared with albuminuria. Results During a median (IQR) 10.7 (6.4, 13.5) years of follow-up, sphingomyelin was independently associated with the fastest eGFR decline (lowest 25%; median [IQR] for eGFR change:
Subject: Albuminuria
Coronary artery disease
Diabetic kidney disease
Glomerular filtration rate
NMR metabolomics
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: unspecified
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
PongracBarlovic ... yelinAndProgressionOfR.pdf 634.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record